New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
04:55 EDTMDVN, MDVN, MDVN, MYGN, MYGN, MYGNAmerican Society of Clinical Oncology to hold symposium
ASCO 2014 Genitourinary (GU) Cancers Symposium is being held in San Francisco on January 30-February 1.
News For MDVN;MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
12:12 EDTMYGNMyriad Genetics receives FDA approval of BRACAnalysis CDx
Myriad Genetics (MYGN) announced that it has received approval from the U.S. FDA for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca's (AZN) drug Lynparza. Lynparza is the first poly ADP-ribose polymerase inhibitor for patients with germline mutations in BRCA1/2 advanced ovarian cancer who have had three or more lines of chemotherapy. BRACAnalysis CDx is Myriad's first FDA-approved companion diagnostic for use with a novel PARP inhibitor. BRACAnalysis CDx is a highly accurate molecular companion diagnostic test that identifies deleterious or suspected deleterious mutations in the BRCA1 and BRCA2 genes, using DNA obtained from a blood sample. BRACAnalysis CDx was proven in clinical studies to effectively identify patients with BRCA mutations who would be candidates for Lynparza. The approval of BRACAnalysis CDx demonstrates Myriad's commitment to developing companion diagnostics and is the culmination of an intensive, multiyear scientific collaboration with AstraZeneca to advance personalized medicine for women with ovarian cancer.
10:17 EDTMYGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:15 EDTMYGNMyriad Genetics initiated with a Market Perform at Wells Fargo
Subscribe for More Information
December 17, 2014
10:21 EDTMYGNMyriad denied appeal to block competing breast cancer tests, Bloombeg reports
Subscribe for More Information
December 15, 2014
08:46 EDTMDVNMedivation price target raised to $128 from $107 at Leerink
Leerink raised its price target for Medivation shares to $128 after the company presented Stage 1 and preliminary Stage 2 data from the Phase II trial of Xtandi in advanced androgen receptor positive triple negative breast cancer. The firm believes the data demonstrate "clear single agent activity with confirmed objective responses" and keeps an Outperform rating on the stock.
December 12, 2014
18:05 EDTMDVNMedivation, Astellas Pharma report data from Phase 2 study of enzalutamide
Subscribe for More Information
December 11, 2014
12:54 EDTMYGNMyriad Genetics management to meet with William Blair
Subscribe for More Information
December 9, 2014
08:48 EDTMDVNMedivation management to meet with Leerink
Subscribe for More Information
07:44 EDTMDVNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use